UCL

# Success

## From lab to market 2026

Advanced Therapies



**Introducing one of the world's largest development pipelines for Advanced Therapy Medicinal Products (ATMP).**




[1]ATMP manufacturing facilities at the cell and vector innovation centre (CVIC), located at the Royal Free Hospital

[2]ATMP manufacturing cell and gene therapy facilities at the Zayed Centre for Research, located at UCL Great Ormond Street Hospital for Children

[3]Cell and Gene Therapy Catapult – facilities also in Braintree, Edinburgh and Stevenage

[4]The ATTC network is coordinated by the Cell and Gene Therapy Catapult and supported by Innovate UK.

# The heart of London's advanced therapies ecosystems

**UCL sits within a uniquely interconnected network of leading hospitals, research institutes and innovation partners across London. This dense ecosystem enables the seamless translation of scientific discovery into clinical impact, supporting the development and delivery of advanced therapies.**

In addition to world-class researchers, frontline practitioners and clinical trial facilities at UCL's partner hospitals, the ecosystem is supported by the Translational Research Office (TRO), the Therapeutic Innovation Networks (TINs) and UCL Ventures, UCL's expert commercialisation partner.

The result of this connected community is an unrivalled global delivery of novel Advanced Therapy Medicinal Products (ATMPs) straight to patients.

# Publicly funded academic research complements our licensing activities and commercial spinout creation

**The scale of UCL, UCL Ventures, and partner hospitals support collectively accelerates progress through the ATMP pipeline, reducing investment risk and maximising successful commercialisation. This is underpinned by robust financial support from both public and private investment.**

Our extensive portfolio of publicly funded projects, supported by UCL and UCL Ventures' Proof of Concept funding schemes, strengthens early and mid-stage academic research and ensures our development pipeline remains one of the strongest in the sector.

The current active portfolio includes **over £70M of funding** invested in Phase I/II trials and preclinical projects, while more than **50 discovery stage projects** are supported through smaller grants.

# Pioneering new technologies for complex therapies

The development of advanced therapies brings new scientific, technical and manufacturing challenges. UCL researchers are driving progress in the next generation of enabling technologies, building the tools and platforms needed to accelerate discovery and translation.



# UCL offers one of the world's most extensive ATMP development pipelines

| Discovery Projects | Preclinical/IND Enabling | Clinical Phase I/II | Clinical Phase III | Launched | Available on the NHS |
|---|---|---|---|---|---|
| 50+ | 29 | 30 | 01 | 02 | 01 |

## Extensive professional support and know-how has enabled projects to attract significant venture capital investment.

Portfolio information accurate as of December 2025.



# Scale and collaboration to strengthen clinical delivery

**Close to 44% of the UK's academically sponsored, non-profit ATMP clinical trials and more than 50% of the UK's commercially sponsored ATMP trials are conducted through UCL partner hospitals, reflecting the depth, capability and confidence of our clinical ecosystem.**

Our network of clinical trial centres and specialist medical facilities provides the infrastructure needed to deliver trials at scale and pace. Strong links with research centres worldwide further enable coordinated activity across multiple territories.

**UK academic/ non-profit trials**




UCL sponsors **44%** of the UK's academically sponsored and non-profit trials

**Commercially sponsored trials**




UCL hospital partners are sites for **51%** of the UK's commercially sponsored trials

Source: Cell and Gene Therapy Catapult ATMP Clinical Trials Database 2025.

# Advanced Therapy Treatment Centre (ATTC) network

**UCL has joined the Advanced Therapy Treatment Centre (ATTC) network as part of the London Advanced Therapies ATTC, working alongside Imperial College London, King's College London and Queen Mary University of London.**

Coordinated by the Cell and Gene Therapy Catapult, the ATTC network addresses the complex challenges of bringing pioneering ATMPs to patients. It is dedicated to making the UK a leading environment for ATMP clinical trials and a global destination for advanced therapy research.

**The ATTC network is a UK-wide group of centres operating within the NHS framework.**

ATTC
Advanced Therapy Treatment Centres

iMATCH
LONDON ADVANCED THERAPIES
Midlands-Wales Advanced Therapy Treatment Centre
Northern Alliance

# Talk to us

Jointly produced by the
UCL Translational Research Office
and UCL Ventures Ltd.

For information about translational research and industry-academia collaborations, speak to the UCL Translational Research Office:

Dr Jane Kinghorn, Director
**j.kinghorn@ucl.ac.uk**

For information about commercialisation, speak to UCL Ventures:

Dr Rick Fagan
**r.fagan@uclventures.com**

Therapeutic
Innovation Networks

**Join TINs**
Scan to enrol as a member of the UCL Therapeutic Innovation Networks (TINs) and receive news and event invitations about therapeutic innovations at UCL:

**tins@ucl.ac.uk**